Moberg Pharma AB (OMX: MOB) today announced its U.S. launch of Kerasal®
NeuroCream, an over the counter pain relieving foot cream. This new
product will be sold in over 3,800 Walmart stores and in CVS, Walgreens,
and Rite Aid drug stores starting late August.
Approximately 30 million Americans experience frequent foot pain 1) and
many simultaneously suffer from cold feet and dry skin. Painful, cold,
dry feet may be associated with various conditions, including diabetes,
fibromyalgia, shingles, arthritis, joint pain, muscle strain, or trauma.
Kerasal® NeuroCream is a triple action formula that relieves stabbing,
burning, tingling foot pain, warms cold feet, and soothes and
moisturizes dry skin. Kerasal® NeuroCream is easily applied with a "no
mess” foam applicator.
The active ingredients of Kerasal® NeuroCream, capsaicin and camphor,
have a well-established use as topical pain relievers, are naturally
occurring and derived from plants. Moberg Pharma has utilized its
Fusome® skin delivery system, currently used in Moberg’s JointFlex® Pain
Relieving Cream, to formulate Kerasal® NeuroCream, enabling a rapid
delivery of effective pain relievers to the pain source.
"Kerasal® NeuroCream is an innovative addition to our product portfolio.
It leverages one of our existing drug delivery technologies along with
proven active ingredients, to provide a solution that meets an unmet
consumer need. Kerasal® NeuroCream further strengthens the Kerasal®
brand, our leadership in the topical OTC foot care space in the U.S. and
our value to retail partners”, said Peter Wolpert, CEO of Moberg Pharma
About this information
Moberg Pharma discloses this information pursuant to the Swedish
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 11.00 am (CET) on August
About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical
company with direct sales through its own sales organization in the US
and sales through distributors in more than 40 countries. The company’s
product portfolio includes topical products for the treatment of skin
disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail®
and Kaprolac®. Kerasal Nail® (Nalox™/Naloc™ in many markets) is the
leading product for the treatment of nail disorders in the Nordic
market. The portfolio is developed further through acquisitions and
in-licensing of products as well as product development with focus on
innovative drug delivery based on proven compounds. Moberg Pharma has
offices in Stockholm and New Jersey and the company’s share (OMX: MOB)
is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange
Stockholm. For further information, please visit: www.mobergpharma.se.
1) The population prevalence of foot and ankle pain in middle and old
age: a systematic review. Thomas et al, Pain 2011 Dec
This information was brought to you by Cision http://news.cision.com